Paper39155294
Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies.
Mongeon B and 8 others. NPJ Syst Biol Appl, 2024. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies. Papers, record 39155294. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39155294
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioblastoma | Major topic |
| Tumor Microenvironment | Major topic |
| Immunotherapy | Major topic |
| Brain Neoplasms | Major topic |
| Computer Simulation | Major topic |
| Humans | |
| Oncolytic Virotherapy | |
| Oncolytic Viruses | |
| Immune Checkpoint Inhibitors |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| RGPIN-2018-04546 | Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada) | RGPIN201804 | PubMed |
Source NIH RePORTER
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15758009 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. | N Engl J Med | 2005 | https://conductscience.org/library/papers/15758009 | PubMed |
| 2 | 26960561 | Survival in glioblastoma: a review on the impact of treatment modalities. | Clin Transl Oncol | 2016 | https://conductscience.org/library/papers/26960561 | PubMed |
| 3 | 35327456 | Assessing the Future of Solid Tumor Immunotherapy. | Biomedicines | 2022 | https://conductscience.org/library/papers/35327456 | PubMed |
| 4 | 17997439 | History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. | J Urol | 2008 | https://conductscience.org/library/papers/17997439 | PubMed |
| 5 | 26056592 | Adoptive T-cell therapy for Leukemia. | Mol Cell Ther | 2014 | https://conductscience.org/library/papers/26056592 | PubMed |
| 6 | 34236546 | Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. | Cancer Metastasis Rev | 2021 | https://conductscience.org/library/papers/34236546 | PubMed |
| 7 | 35337133 | Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/35337133 | PubMed |
| 8 | 32266483 | Oncolytic Viruses for the Treatment of Metastatic Melanoma. | Curr Treat Options Oncol | 2020 | https://conductscience.org/library/papers/32266483 | PubMed |
| 9 | 32004650 | Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. | J Am Acad Dermatol | 2020 | https://conductscience.org/library/papers/32004650 | PubMed |
| 10 | 26059190 | Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/26059190 | PubMed |
| 11 | 32437507 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32437507 | PubMed |
| 12 | 35511454 | Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. | Neuro Oncol | 2022 | https://conductscience.org/library/papers/35511454 | PubMed |
| 13 | 31289361 | Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. | Oncogene | 2019 | https://conductscience.org/library/papers/31289361 | PubMed |
| 14 | 35637733 | Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy. | iScience | 2022 | https://conductscience.org/library/papers/35637733 | PubMed |
| 15 | 37853118 | Clinical trial links oncolytic immunoactivation to survival in glioblastoma. | Nature | 2023 | https://conductscience.org/library/papers/37853118 | PubMed |
| 16 | 30261620 | The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/30261620 | PubMed |
| 17 | 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 | https://conductscience.org/library/papers/37188783 | PubMed |
| 18 | 33608375 | In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/33608375 | PubMed |
| 19 | 20234341 | Synergistic interaction between oncolytic viruses augments tumor killing. | Mol Ther | 2010 | https://conductscience.org/library/papers/20234341 | PubMed |
| 20 | 19603003 | Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. | Mol Ther | 2009 | https://conductscience.org/library/papers/19603003 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41557745 | Therapeutic targeting of oligodendrocytes in an agent-based model of multiple sclerosis. | PLoS Comput Biol | 2026 | https://conductscience.org/library/papers/41557745 | PubMed |
| 41501087 | Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment. | NPJ Syst Biol Appl | 2026 | https://conductscience.org/library/papers/41501087 | PubMed |
| 41270976 | Informing development of brain cancer therapies within "preclinical trials" using ex vivo patient tumors. | Adv Drug Deliv Rev | 2026 | https://conductscience.org/library/papers/41270976 | PubMed |
| 41080585 | Targeting immune cell migration as therapy for inflammatory disease: a review. | Front Immunol | 2025 | https://conductscience.org/library/papers/41080585 | PubMed |
| 41030523 | Targeting the tumor microenvironment in pediatric gliomas: Advances and future directions in immunotherapy. | Neurooncol Adv | 2025 | https://conductscience.org/library/papers/41030523 | PubMed |
| 40995359 | Targeting the neuroimmune axis in glioblastoma: emerging strategies for precision immunotherapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/40995359 | PubMed |
| 40907963 | Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling. | J Am Med Inform Assoc | 2026 | https://conductscience.org/library/papers/40907963 | PubMed |
| 40840524 | Systems biology successes and areas for opportunity in prostate cancer. | Endocr Relat Cancer | 2025 | https://conductscience.org/library/papers/40840524 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39155294
GET https://conductscience.org/api/papers/v1/39155294/references?page=2